Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Sapporo Clinical Laboratory (TSE:9776) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Sapporo Clinical Laboratory's EV-to-EBIT for today is
Sapporo Clinical Laboratory's current Enterprise Value is 円4,780 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sapporo Clinical Laboratory's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was 円752 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Sapporo Clinical Laboratory's EV-to-EBITDA for today is:
Sapporo Clinical Laboratory's current Enterprise Value is 円4,780 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sapporo Clinical Laboratory's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was 円1,378 Mil.
Sapporo Clinical Laboratory's current Enterprise Value is 円4,780 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sapporo Clinical Laboratory's Revenue for the trailing twelve months (TTM) ended in Sep. 2025 was 円20,372 Mil.
Sapporo Clinical Laboratory's current Enterprise Value is 円4,780 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sapporo Clinical Laboratory's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2025 was 円1,040 Mil.
Sapporo Clinical Laboratory's current Enterprise Value is 円4,780 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sapporo Clinical Laboratory's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was 円173 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory Enterprise Value Related Terms
Sapporo Clinical Laboratory Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory Enterprise Value Chart
Sapporo Clinical Laboratory Enterprise Value Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sapporo Clinical Laboratory's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sapporo Clinical Laboratory Enterprise Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sapporo Clinical Laboratory's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Sapporo Clinical Laboratory's Enterprise Value falls into.
Sapporo Clinical Laboratory Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory (TSE:9776) has a Enterprise Value of 円4,780 Mil as of Jul. 20, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sapporo Clinical Laboratory and its competitors.
Is Sapporo Clinical Laboratory's Enterprise Value too high?
Sapporo Clinical Laboratory's current Enterprise Value is 円4,780 Mil. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's Enterprise Value compare to competitors?
Sapporo Clinical Laboratory's Enterprise Value of 円4,780 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Healthcare Providers & Services company?
A good Enterprise Value depends on the Healthcare Providers & Services industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sapporo Clinical Laboratory and its competitors. Sapporo Clinical Laboratory's current Enterprise Value is 円4,780 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current Enterprise Value of 円4,780 Mil. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current Enterprise Value is 円4,780 Mil. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current Enterprise Value is 円4,780 Mil as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?
Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued.
The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.
Key valuation signals for TSE:9776:
Enterprise Value: 円4,780 Mil
GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score
Get the complete analysis for TSE:9776
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9776 has been successfully added to your 
